5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas
- PMID: 30097823
- DOI: 10.1007/s11060-018-2956-8
5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas
Abstract
Introduction: Fluorescence guided surgery (FGS) with five-aminolevulinic acid (5-ALA) is expected to revolutionize neurosurgical care of patients with high-grade gliomas (HGG). After the recent landmark FDA approval, this optical agent is now available to neurosurgeons in the United States.
Methods: This review is designed to highlight the evidence for the use of 5-ALA in recurrent HGG surgery for the neurosurgical community. The manuscript was prepared in accordance with the PRISMA guidelines.
Results: Intra-operatively, a strong fluorescent signal is highly correlated with the presence of cellular tumor in recurrent HGG, giving it a high positive predictive value (PPV). Similar to what is observed in primary HGG surgery, false-negative results can occur if tumor cells do not emit fluorescence. In addition, false-positive fluorescence signals in tissues devoid of tumor cells can be observed more frequently in recurrent HGG compared to the primary setting. However, these areas overwhelmingly contain reactive/regressive tissue, resection of which is unlikely to cause functional deficits. The safety profile of 5-ALA is similarly favorable in primary and recurrent HGG.
Conclusions: 5-ALA FGS is a powerful adjunct in the resection of recurrent HGG with a high PPV and favorable safety profile. It is therefore the authors' opinion to routinely employ this fluorescent agent as a standard of care.
Keywords: Five-aminolevulinic acid (5-ALA); Fluorescence guided surgery (FGS); Neurosurgery; Recurrent anaplastic astrocytoma; Recurrent glioblastoma; Recurrent high grade glioma.
Similar articles
-
A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.J Neurosurg. 2016 May;124(5):1300-9. doi: 10.3171/2015.5.JNS1577. Epub 2015 Nov 6. J Neurosurg. 2016. PMID: 26544781 Clinical Trial.
-
The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience.J Neurooncol. 2019 Feb;141(3):507-515. doi: 10.1007/s11060-018-03061-3. Epub 2018 Dec 1. J Neurooncol. 2019. PMID: 30506501
-
5-Aminolevulinic acid for recurrent malignant gliomas: A systematic review.Clin Neurol Neurosurg. 2020 Aug;195:105913. doi: 10.1016/j.clineuro.2020.105913. Epub 2020 May 16. Clin Neurol Neurosurg. 2020. PMID: 32447151
-
5-ALA and FDA approval for glioma surgery.J Neurooncol. 2019 Feb;141(3):479-486. doi: 10.1007/s11060-019-03098-y. Epub 2019 Jan 14. J Neurooncol. 2019. PMID: 30644008 Free PMC article. Review.
-
Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.J Neurooncol. 2022 Jan;156(2):233-256. doi: 10.1007/s11060-021-03901-9. Epub 2022 Jan 6. J Neurooncol. 2022. PMID: 34989964 Review.
Cited by
-
The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions.Neuro Oncol. 2023 Dec 8;25(12):2117-2133. doi: 10.1093/neuonc/noad133. Neuro Oncol. 2023. PMID: 37499054 Free PMC article.
-
5-Aminolevulinic Acid Hydrochloride (5-ALA)-Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment.Ont Health Technol Assess Ser. 2020 Mar 6;20(9):1-92. eCollection 2020. Ont Health Technol Assess Ser. 2020. PMID: 32194883 Free PMC article.
-
High Interobserver Agreement in the Subjective Classification of 5-Aminolevulinic Acid Fluorescence Levels in Newly Diagnosed Glioblastomas.Lasers Surg Med. 2020 Nov;52(9):814-821. doi: 10.1002/lsm.23228. Epub 2020 Mar 8. Lasers Surg Med. 2020. PMID: 32147864 Free PMC article.
-
Pharmaceutical equivalent 5-aminolevulinic acid fluorescence guided resection of central nervous system tumors: feasibility, safeness and cost-benefit considerations.J Neurooncol. 2024 Jul;168(3):555-562. doi: 10.1007/s11060-024-04698-z. Epub 2024 May 6. J Neurooncol. 2024. PMID: 38709355
-
Fluorescent Guided Surgery in the Surgical Management of Glioma: The Dawn of a New Era.Brain Sci. 2020 Apr 16;10(4):237. doi: 10.3390/brainsci10040237. Brain Sci. 2020. PMID: 32316309 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical